var data={"title":"Carmustine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Carmustine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5828?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=carmustine-drug-information\" class=\"drug drug_general\">see &quot;Carmustine: Drug information&quot;</a> and <a href=\"topic.htm?path=carmustine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Carmustine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708652\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Myelosuppression (injection)</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Carmustine causes suppression of marrow function (including thrombocytopenia and leukopenia), which may contribute to bleeding and overwhelming infections. Monitor blood counts weekly for at least 6 weeks after each dose. Adjust dosage based on nadir blood counts from the prior dose. Do not administer a repeat course of carmustine until blood counts recover.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pulmonary toxicity (injection)</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Carmustine causes dose-related pulmonary toxicity. Patients receiving greater than 1,400 mg/m<sup>2</sup> cumulative dose are at significantly higher risk than those receiving less. Delayed pulmonary toxicity can occur years after treatment, and can result in death, particularly in patients treated in childhood.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146512\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>BiCNU;</li>\n      <li>Gliadel Wafer</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146513\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>BiCNU;</li>\n      <li>Gliadel Wafer</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045770\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Alkylating Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Alkylating Agent (Nitrosourea)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045762\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=carmustine-drug-information\" class=\"drug drug_general\">see &quot;Carmustine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Children are at increased risk for pulmonary toxicity due to carmustine, weigh risk vs benefit before use. Refer to individual protocols; dosing and frequency may vary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Brain tumors, myeloablative therapy prior to autologous stem cell rescue:</b> Very limited data available; Infants, Children, and Adolescents: IV: 100 mg/m<sup>2</sup>/dose twice daily for 3 days (total: 600 mg/m<sup>2</sup>) as part of a high dose combination chemotherapy regimen is most commonly reported in trials with mixed results (Dunkel 1998; Finlay 2008); however, a phase I trial identified a lower dose of 100 mg/m<sup>2</sup>/dose once daily for 3 days (total: 300 mg/m<sup>2</sup>) in combination with thiotepa as the maximum tolerated regimen with a high degree of pulmonary toxicity observed (Gilman 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Non-Hodgkin lymphoma; relapsed or resistant, high-dose chemotherapy prior to autologous bone marrow transplant:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">BEAM regimen: Adolescents &ge;15 years: IV: 300 mg/m<sup>2</sup>/dose for 1 dose followed by etoposide, cytarabine, and melphalan (Mills 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CBV regimen: Children and Adolescents: IV: 100 mg/m<sup>2</sup>/dose once daily for 3 days (total dose: 300 mg/m<sup>2</sup>) on days -8 through -6 in combination with cyclophosphamide and etoposide (Harris 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Brain tumors, Hodgkin lymphoma, multiple myeloma, non-Hodgkin lymphoma:</b> IV: 150 to 200 mg/m<sup>2</sup> every 6 weeks or 75 to 100 mg/m<sup>2</sup>/day for 2 days every 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Glioblastoma multiforme (recurrent), newly-diagnosed high-grade malignant glioma:</b> Implantation (wafer): 8 wafers (7.7 mg each) implanted intracranially into the resection cavity (total dose: 61.6 mg); should the size and shape not accommodate 8 wafers, the maximum number of wafers allowed (up to 8) should be placed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity:</b> The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic toxicity: Based on nadir counts with previous dose (manufacturer's labeling). IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If leukocytes &ge;3,000/mm<sup>3</sup> and platelets &ge;75,000/mm<sup>3</sup>: Administer 100% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If leukocytes 2,000 to 2,999/mm<sup>3</sup> or platelets 25,000 to 74,999/mm<sup>3</sup>: Administer 70% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If leukocytes &lt;2,000/mm<sup>3</sup> or platelets &lt;25,000/mm<sup>3</sup>: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: There are no dosage adjustments provided in the manufacturer's labeling. The following dosage adjustments have been reported (Kintzel 1995):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 46 to 60 mL/minute: Administer 80% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 31 to 45 mL/minute: Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &le;30 mL/minute: Consider use of alternative drug</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Wafer implant: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Dosage adjustment may be necessary; however, no specific guidelines are available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Wafer implant: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146489\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">BiCNU: 100 mg (1 ea) [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Wafer, Implant: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gliadel Wafer: 7.7 mg (8 ea) [contains polifeprosan 20]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146473\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045774\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Infuse over 2 hours (infusions &lt;2 hours may lead to injection site pain or burning); infuse through a free-flowing saline or dextrose infusion, or administer through a central catheter to alleviate venous pain/irritation. Significant absorption to PVC containers; should be prepared in either glass or polyolefin containers.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">High-dose carmustine (transplant dose): Infuse over at least 2 hours to avoid excessive flushing, agitation, and hypotension; was infused over 1 hour in some trials (Chopra 1993). High-dose carmustine may be fatal if not followed by stem cell rescue. Monitor vital signs frequently during infusion; patients should be supine during infusion and may require the Trendelenburg position, fluid support, and vasopressor support.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Wafer: Double glove before handling; outer gloves should be discarded as chemotherapy waste after handling wafers. Any wafer or remnant that is removed upon repeat surgery should be discarded as chemotherapy waste. The outer surface of the external foil pouch is not sterile. Open pouch gently; avoid pressure on the wafers to prevent breakage. Wafers that are broken in half may be used, however, wafers broken into more than 2 pieces should be discarded in a biohazard container. Oxidized regenerated cellulose (Surgicel) may be placed over the wafer to secure; irrigate cavity prior to closure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130925\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).   </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and (if applicable) closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146505\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Store intact vials and provided diluent at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Carmustine has a low melting point (30.5&deg;C to 32&deg;C [86.9&deg;F to 89.6&deg;F]); exposure to temperature at or above the melting point will cause the drug to liquefy and appear as an oil film on the vials; if drug liquefies, discard the vials as this is a sign of decomposition. If there is a question of proper refrigeration upon receipt of product, inspect vials; a small amount of dry flakes or dry congealed mass is acceptable and the vial should be refrigerated immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Reconstituted solutions are stable for 24 hours refrigerated (2&deg;C to 8&deg;C) and protected from light. Examine reconstituted vials for crystal formation prior to use. If crystals are observed, they may be redissolved by warming the vial to room temperature with agitation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solutions diluted for infusion to a concentration of 0.2 mg/mL in D5W or NS in glass or polypropylene containers and protected from light should be used within 8 hours when stored at room temperature (25&deg;C); infusion solutions are also stable for 24 hours refrigerated followed by an additional 6 hours at room temperature. Although the manufacturer recommends glass or polypropylene containers be used, stability of a 1 mg/mL solution in D5W has also been demonstrated for up to 6 hours (with a 6% to 7% loss of potency) in polyolefin containers (Trissel 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Wafer: Store at or below -20&deg;C (-4&deg;F). Unopened outer foil pouches may be kept at room temperature for up to 6 hours at a time for up to 3 cycles within a 30-day period.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045773\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Treatment of brain tumors (glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumor); multiple myeloma, Hodgkin lymphoma, and non-Hodgkin lymphomas (relapsed or refractory) (FDA approved in adults); has also been used for myeloablative therapy prior to stem cell transplant</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Wafer (implant): Adjunct to surgery in patients with recurrent glioblastoma multiforme; adjunct to surgery and radiation in patients with newly diagnosed high grade malignant glioma (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2136823\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Carmustine may be confused with bendamustine, lomustine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146557\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Implant:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Cerebral edema, cerebral hemorrhage, depression, intracranial hypertension, meningitis, seizure (less common with new or worsening)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain, constipation, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Abscess</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever, wound healing impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain, flushing (with rapid infusion), occlusive arterial disease, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Brain disease, headache, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia, burning sensation of skin, hyperpigmentation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia, diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Gynecomastia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Acute leukemia, anemia, bone marrow dysplasia, leukemia, leukopenia (common; onset: 5 to 6 weeks; recovery: after 1 to 2 weeks), thrombocytopenia (common: onset: ~4 weeks; recovery: after 1 to 2 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum alkaline phosphatase, increased serum bilirubin, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Opportunistic infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Burning sensation at injection site, erythema at injection site, pain at injection site, swelling at injection site, tissue necrosis at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision, conjunctival edema, conjunctival hemorrhage, ophthalmic signs and symptoms (loss of depth perception), suffusion of the conjunctiva (with rapid infusion)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Azotemia (progressive), nephron atrophy, renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Interstitial pulmonary disease, pneumonitis, pulmonary fibrosis (occurring up to 17 years after treatment), pulmonary infiltrates</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Febrile neutropenia (Chopra 1993), sepsis (implant), venous thrombosis at injection site (IV)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146495\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Hypersensitivity to carmustine or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Implant: There are no contraindications listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146477\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: <b>[US Boxed Warning]: Carmustine IV causes bone marrow suppression, primarily thrombocytopenia (which may lead to bleeding) and leukopenia (which may cause infection). Monitor blood counts weekly for at least 6 weeks following each dose. Adjust dosage based on nadir blood counts from prior dose for dosage adjustment. Do not administer a repeat course until blood counts recover.</b> Hematologic toxicity is dose-limiting, may be severe, and is generally delayed and cumulative; thrombocytopenia is usually more severe than leukopenia. Myelosuppression generally occurs 4 to 6 weeks after administration; thrombocytopenia occurs at ~4 weeks and persists for 1 to 2 weeks; leukopenia occurs at 5 to 6 weeks and persists for 1 to 2 weeks. Anemia may occur (less common and less severe than leukopenia or thrombocytopenia). Platelet counts should be &gt;100,000/mm<sup>3</sup> and leukocytes should be &gt;4,000/mm<sup>3</sup> prior to a repeat course (repeat courses should not be administered more frequently than every 6 weeks).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Carmustine IV is associated with a moderate to high emetic potential (dose-related); antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011; Hesketh 2017; Roila 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic: Reversible increases in transaminases, bilirubin, and alkaline phosphatase have been reported (rare) with the IV formulation. Monitor liver function tests periodically during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion-site reactions: Rapid infusions are associated with skin flushing and suffusion of the conjunctiva (onset: &lt;2 hours; duration ~4 hours). Carmustine is also associated with injection-site burning and local tissue reactions, including swelling, pain, erythema, and necrosis, have been reported. Monitor infusion site closely for infiltration or injection-site reactions. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intracranial hypertension: Brain edema has been reported in patients with newly diagnosed glioma receiving wafer implants, including one report of intracranial mass effect unresponsive to corticosteroids that led to brain herniation. Monitor closely for intracranial hypertension related to brain edema, inflammation, or necrosis of brain tissue surrounding resection. Re-operation to remove wafers (or remnants) may be necessary for refractory cases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Meningitis: Cases of meningitis have occurred in patients with recurrent glioma receiving wafer implants. Two cases were bacterial (one patient required removal of implants 4 days after implantation and the other developed meningitis following reoperation for recurrent tumor). Another case was determined to be chemical meningitis and resolved with corticosteroids. Monitor postoperatively for signs/symptoms of meningitis and CNS infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular toxicity: Investigational administration (intraarterial intracarotid route [not an approved route]) has been associated with ocular toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: <b>[US Boxed Warning]: Carmustine IV is associated with dose-related pulmonary toxicity; patients receiving cumulative doses &gt;1,400 mg/m<sup>2</sup> are at significantly higher risk. Delayed onset of pulmonary fibrosis may occur years after treatment (may be fatal), particularly in children.</b> Pulmonary toxicity has occurred in children and adolescents up to 17 years after treatment; this occurred in ages 1 to 16 for the treatment of intracranial tumors; cumulative doses ranged from 770 to 1,800 mg/m<sup>2</sup> (in combination with cranial radiotherapy). Pulmonary toxicity is characterized by pulmonary infiltrates and/or fibrosis and has been reported from 9 days to 43 months after nitrosourea treatment (including carmustine). Although pulmonary toxicity generally occurs in patients who have received prolonged treatment, pulmonary fibrosis has been reported with cumulative doses below 1,400 mg/m<sup>2</sup>. Interstitial fibrosis at lower doses has occurred (rare). In addition to high cumulative doses, other risk factors for pulmonary toxicity include history of lung disease and baseline predicted forced vital capacity (FVC) or carbon monoxide diffusing capacity (DLCO) &lt;70%. Baseline and periodic pulmonary function tests are recommended. For high-dose treatment (transplant; off-label dose), acute lung injury may occur ~1 to 3 months post transplant; advise patients to contact their transplant physician for dyspnea, cough, or fever; interstitial pneumonia may be managed with a course of corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal: Renal failure, progressive azotemia, and decreased kidney size have been reported in patients who have received large cumulative IV doses or prolonged IV treatment. Renal toxicity has also been reported in patients who have received lower cumulative doses. Monitor renal function tests periodically during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancies: Long-term IV use is associated with the development of secondary malignancies (acute leukemias and bone marrow dysplasias).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Seizures occurred in patients who received carmustine wafer implants, including new or worsening seizures and treatment-emergent seizures. Just over half of treatment-emergent seizures occurred within 5 days of surgery; the median onset of first new or worsened post-operative seizure was 4 days. Optimal anti-seizure therapy should be initiated prior to surgery. Monitor (postoperatively) for seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Wound healing impairment: Impaired neurosurgical wound healing, including would dehiscence, delayed healing, and subdural, subgleal or wound effusions may occur with carmustine wafer implant treatment; cerebrospinal fluid leaks have also been reported. Monitor post-operatively for impaired neurosurgical wound healing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Disease related concerns:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: May require dosage adjustment or discontinuation in patients with renal impairment. Do not administer carmustine IV in patients with compromised renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Children are at higher risk of delayed pulmonary toxicity with the IV formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: Diluent contains ethanol.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Wafer: Monitor closely for known craniotomy-related complications (seizure, intracranial infection, abnormal wound healing, brain edema). Wafer migration may occur; avoid communication between the resection cavity and the ventricular system to prevent wafer migration; communications larger than the wafer should be closed prior to implantation; wafer migration into the ventricular system may cause obstructive hydrocephalus. Monitor for signs/symptoms of obstructive hydrocephalus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298978\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146483\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13118&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May enhance the myelosuppressive effect of Carmustine. Management: Consider alternatives to cimetidine in patients receiving carmustine.  If the combination cannot be avoided, monitor for enhanced carmustine myelotoxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Melphalan: May enhance the adverse/toxic effect of Carmustine. Specifically, melphalan may sensitize patients to carmustine lung toxicity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146485\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146498\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Based on the mechanism of action, carmustine may cause fetal harm if administered to a pregnant woman. Females of reproductive potential should use highly effective contraceptives during and for at least 6 months following treatment. Males of reproductive potential should use highly effective contraceptives during and for at least 3 months following treatment. May impair male fertility. Advise males of potential risk of infertility and to seek fertility/family planning counseling prior to receiving carmustine wafer implants.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045769\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelet count (weekly for at least 6 weeks after a dose), pulmonary function tests (FVC, DLCO; at baseline and frequently during treatment), liver function (periodically), renal function tests (periodically); monitor blood pressure and vital signs during administration, monitor infusion site for possible infiltration</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Wafer: Complications of craniotomy (seizures, intracranial infection, brain edema)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146476\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Carmustine interferes with the normal function of DNA and RNA by alkylation and cross-linking the strands of DNA and RNA, and by possible protein modification; may also inhibit enzyme processes by carbamylation of amino acids in protein.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146494\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: IV: 3.3 L/kg; readily crosses blood-brain barrier producing CSF levels &ge;50% of blood plasma levels; highly lipid soluble</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Rapidly hepatic; forms active metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IV: 15 to 75 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: IV: Urine (~60% to 70%) within 96 hours; lungs (~10% as CO<sub>2</sub>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5100296\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (BiCNU Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $4,716.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Wafer</b> (Gliadel Wafer Implant)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.7 mg (8): $36,583.48</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146500\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bcnu (BG, HN);</li>\n      <li>Becenun (BR, FI, NO);</li>\n      <li>BiCNU (AR, CO, CZ, FR, GB, IE, KR, MX, NZ, PH, PT, TW, UY, ZA);</li>\n      <li>BICNU (BB, EC, VN);</li>\n      <li>Bicnu (CL, HU);</li>\n      <li>Carmubris (AT, DE);</li>\n      <li>Gliadel (GR, HK, IE, IL, IT, JP, MY, NL, SG, TH, TW);</li>\n      <li>Gliadel Implant (AU, ES);</li>\n      <li>Nitrumon (BE, LU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronin PA, Mahaley MS Jr, Rudnick SA, et al, &ldquo;Prediction of BCNU Pulmonary Toxicity in Patients With Malignant Gliomas,&rdquo; <i>N Engl J Med</i>, 1980, 303(4):183-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-pediatric-drug-information/abstract-text/7383088/pubmed\" target=\"_blank\" id=\"7383088\">7383088</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2011;29(31):4189-4198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-pediatric-drug-information/abstract-text/21947834/pubmed\" target=\"_blank\" id=\"21947834\">21947834</a>]</span><span class=\"doi\">10.1200/JCO.2010.34.4614</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    BiCNU (carmustine) [prescribing information]. Edison, NJ: Heritage Pharmaceuticals; April 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chopra R, McMillan AK, Linch DC, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. <i>Blood</i>. 1993;81(5):1137-1145</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Colvin M, Hartner J, and Summerfield M, &ldquo;Stability of Carmustine in the Presence of Sodium Bicarbonate,&rdquo; <i>Am J Hosp Pharm</i>, 1980, 37(5):677-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-pediatric-drug-information/abstract-text/7386477/pubmed\" target=\"_blank\" id=\"7386477\">7386477</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dunkel IJ, Garvin JH Jr, Goldman S, et al, &ldquo;High Dose Chemotherapy With Autologous Bone Marrow Rescue for Children With Diffuse Pontine Brain Stem Tumors. Children's Cancer Group,&rdquo; <i>J Neurooncol</i>, 1998, 37(1):67-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-pediatric-drug-information/abstract-text/9525840/pubmed\" target=\"_blank\" id=\"9525840\">9525840</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-pediatric-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Favier M, De Cazanove F, Coste A, et al, &quot;Stability of Carmustine in Polyvinyl Chloride Bags and Polyethylene-Lined Trilayer Plastic Containers,&quot; <i>Am J Health Syst Pharm</i>, 2001, 58(3):238-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-pediatric-drug-information/abstract-text/11217179/pubmed\" target=\"_blank\" id=\"11217179\">11217179</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Finlay JL, DHall G, Boyett JM, Dunkel IJ, Gardner SL, Goldman S, et al. Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children&rsquo;s Oncology Group. <i>Pediatr Blood Cancer</i>. 2008;51:806-811.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-pediatric-drug-information/abstract-text/18802947/pubmed\" target=\"_blank\" id=\"18802947\">18802947</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilman AL, Jacobsen C, Bunin N, Levine J, Goldman F, Bendel A, et al. Phase I study of tandem high-dose chemotherapy with autologous peripheral blood stem cell rescue for children with recurrent brain tumors: a pediatric blood and marrow transplant consortium study. <i>Pediatr Blood Cancer</i>. 2011;57:506-513.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-pediatric-drug-information/abstract-text/21744474/pubmed\" target=\"_blank\" id=\"21744474\">21744474</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gliadel (carmustine) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; November 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al. Appropriate Chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>J Clin Oncol</i>. 2012;30(13):1553-1561.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-pediatric-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harris RE, Termuhlen AM, Smith LM, et al. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962. <i>Biol Blood Marrow Transplant</i>. 2011;17(2):249-258.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-pediatric-drug-information/abstract-text/20637881/pubmed\" target=\"_blank\" id=\"20637881\">20637881</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. <i>Cancer Treat Rev</i>. 1995;21(1):33-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-pediatric-drug-information/abstract-text/7859226/pubmed\" target=\"_blank\" id=\"7859226\">7859226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH.  BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. <i>J Clin Oncol</i>. 1995;13(3):588-595.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-pediatric-drug-information/abstract-text/7884420/pubmed\" target=\"_blank\" id=\"7884420\">7884420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Driscoll BR, Hasleton PS, Taylor PM, et al, &ldquo;Active Lung Fibrosis Up to 17 Years After Chemotherapy With Carmustine (BCNU) in Childhood,&rdquo; <i>N Engl J Med</i>, 1990, 323(6):378-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-pediatric-drug-information/abstract-text/2370889 /pubmed\" target=\"_blank\" id=\"2370889 \">2370889 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Papadakis V, Dunkel IJ, Cramer LD, et al, &quot;High-Dose Carmustine, Thiotepa and Etoposide Followed by Autologous Bone Marrow Rescue for the Treatment of High Risk Central Nervous System Tumors,&quot; <i>Bone Marrow Transplant</i>, 2000, 26(2):153-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-pediatric-drug-information/abstract-text/10918425/pubmed\" target=\"_blank\" id=\"10918425\">10918425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13118 Version 137.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708652\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F146512\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F146513\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045770\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045762\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F146489\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F146473\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045774\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130925\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F146505\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045773\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2136823\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F146557\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F146495\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F146477\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298978\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F146483\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F146485\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F146498\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1045769\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F146476\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F146494\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5100296\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F146500\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13118|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=carmustine-drug-information\" class=\"drug drug_general\">Carmustine: Drug information</a></li><li><a href=\"topic.htm?path=carmustine-patient-drug-information\" class=\"drug drug_patient\">Carmustine: Patient drug information</a></li></ul></div></div>","javascript":null}